Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 18, Issue 6, 1999, Pages 432-435

  Cuenca Estrella, M ^a   Diaz Guerra T M ^a   Mellado, E ^a   Monzon A ^a   Rodriguez Tudela J L ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CONTROLLED STUDY; DRUG POTENCY; DRUG RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SPAIN;

ANTIFUNGAL AGENTS; CANDIDA; DRUG RESISTANCE, MICROBIAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SPAIN; TRIAZOLES;

EID: 0032750431     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100960050313     Document Type: Article

References (15)

1. 1. Edwards JE Jr: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clinical Infectious Diseases (1997) 25:43-59
2. 2. Barry AL, Brown SD: In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy (1996) 40:1948-1949
3. 3. Belanger P, Nast CC, Fratti R, Sanati H, Ghannoum M: Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrobial Agents and Chemotherapy (1997) 41:1840-1842
4. 4. Espinel-Ingroff A: In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Journal of Clinical Microbiology (1998) 36:198-202
5. 5. Martin MV, Yates J, Hitchcock CA: Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrobial Agents and Chemotherapy (1997) 41:13-16
6. 6. Ruhnke M, Schmidt-Westhausen A, Trautmann M: In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy (1997) 41:575-577
7. 7. Hegener P, Troke PF, Fätkenheuer G, Diehl V, Ruhnke M: Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS (1998) 12:2227-2241
8. 8. Caillot D, Casasnovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, Solary E, Piard F, Petrella T, Bonnin A, Couillault G, Dumas M, Guy H: Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology (1997) 15:139-147
9. 9. Schwartz S, Milatovic D, Thiel E: Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. British Journal of Haematology (1997) 97:663-665
10. 10. Kauffman CA, Zarins LT: In vitro activity of voriconazole against Candida species. Diagnostic Microbiology and Infectious Disease (1998) 31:297-300
11. 11. Marco F, Pfaller MA, Messer S, Jones RN: In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy (1998) 42:161-163
12. 12. Nguyen MH, Yu CY: Voriconazole against fluconazole-susceptible and resistant Candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole. Journal of Antimicrobial Chemotherapy (1998) 42:253-256
13. 13. National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A. NCCLS, Villanova, PA (1997)
14. 14. Rodríguez-Tudela JL, Martínez-Suárez JV: Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrobial Agents and Chemotherapy (1994) 38:45-48
15. 15. Rodríguez-Tudela JL, Martínez-Suárez JV, Dronda F, Laguna F, Chaves F, Valencia E: Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. Journal of Antimicrobial Chemotherapy (1995) 35:793-804